Sirukumab
- Generic Name
- Sirukumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1194585-53-9
- Unique Ingredient Identifier
- 640443FU93
- Background
Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 212
- Registration Number
- NCT04380961
- Locations
- 🇺🇸
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Beaumont Health Systems, Royal Oak, Michigan, United States
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02899026
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02794519
- Locations
- 🇪🇸
GSK Investigational Site, Santiago De Compostela. La Coruña., Spain
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 161
- Registration Number
- NCT02531633
- Locations
- 🇬🇧
GSK Investigational Site, Reading, United Kingdom
A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01636557
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
- First Posted Date
- 2012-05-28
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 878
- Registration Number
- NCT01606761
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1670
- Registration Number
- NCT01604343
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath